Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy
Open Access
- 1 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 8 (6) , ofab297
Abstract
Few instances of treatment-emergent resistance to bictegravir have been reported in the literature. We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.Keywords
This publication has 9 references indexed in Scilit:
- HIV Glasgow – Virtual, 5–8 October 2020Journal of the International AIDS Society, 2020
- Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patientAntiviral Research, 2020
- Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/IJournal of Antimicrobial Chemotherapy, 2019
- Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but PossibleOpen Forum Infectious Diseases, 2018
- HIV drug resistance against strand transfer integrase inhibitorsRetrovirology, 2017
- Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileAntimicrobial Agents and Chemotherapy, 2016
- Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative CapacityAntimicrobial Agents and Chemotherapy, 2015
- Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitorsAIDS, 2014
- Common mental health problems and antiretroviral therapy adherenceAIDS Care, 2011